Briana Contreras

Debra Patt, MD, PhD, MBA, explains how clinical practice has adapted to the use of targeted therapies to treat HER2-positive metastatic breast cancer.

Debra Patt, MD, PhD, MBA, discusses the cost considerations of conventional and novel therapies for HER2-positive metastatic breast cancer.

As COVID-19 precautions are dwindling throughout the world, this upcoming flu season could re-heighten those precautions.

Jennifer Sheets, CEO of Interim Healthcare and Caring Brands International, says a preventable hospital error led to her father’s death: “My commitment and passion for high-quality, process-driven healthcare (are) still greatly fueled by the horrific event that absolutely didn’t need to happen.”

Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Summit Health’s Chief Quality Officer Ashish D. Parikh, MD, and Chief of Population Health Jamie Reedy, MD, in this episode of Tuning In to the C-Suite. In the conversation, the three discussed value-based care programs and contracts within Summit Health and what it takes to invest and implement these programs into your healthcare organization.

Eric Hunter, MBA, CEO of CareOregon, say that “building relationships with people through professional organizations and prior assignments kept me on the radar for the right opportunities.”

An expert in HER2-positive metastatic breast cancer discusses the new targeted treatment regimens for patients.

Debra Patt, MD, PhD, MBA, describes the frontline standards of care and the factors involved in deciding on a treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer.

Sixty percent of patients likely to move forward with a healthcare decision not recommended by their physician, according to a TrialJectory Survey.

In this week's episode, Associate Editor, Briana Contreras spoke with Dr. Florian Otto, co-founder and CEO for Cedar, a complete healthcare financial engagement platform. Dr. Otto discussed the topic of compassionate billing and how this particular payment model is becoming triumphant over traditional healthcare payment models where patients are experiencing an increase in insurance deductibles and out-of-pocket medical expenses.

International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.

MHE Associate Editor, Briana Contreras, spoke with CEO of Inteliquet, a cancer solutions provider that strives to match patients to clinical trials accurately and promptly in healthcare, Marie Lamont. In this episode Marie discusses the challenges that have affected clinical trials and cancer screenings and how to get trials back on track through technology to avoid the wave of undiagnosed patients post-COVID. She also shared how broadening them through diversity can improve trials.

Data presented at the virtual Sleep 2021 meeting by the Annual American Academy of Sleep Medicine suggests treating sleep apnea or obstructive sleep apnea is important for heart health and better prevents chances of COVID-19.

In this week's episode of "Tuning In to the C-Suite" podcast, Managed Healthcare Executive Senior Editor, Peter Wehrwein and Associate Editor, Briana Contreras, spoke with yet another Editorial Advisory Board Member for a segment of the "Meet the Board" series. The two had the pleasure of chatting with Meg Murray, M.P.A., founding CEO of the Association for Community Affiliated Plans, about her journey in healthcare, her organization and were able to look into some of her views about the ACA, equity and racism in healthcare and the Biden Administration’s effects on healthcare.

The impact of the COVID-19 pandemic on the utilization of newer targeted therapies for HER2-positive metastatic breast cancer and considerations regarding their adoption into clinical practice based on the availability of vaccines.

The rationale for treating metastatic breast cancer with a dual HER2-targeted therapy approach.

Briana Contreras, associate editor of MHE, spoke with Edmundo Gonzalez, CEO of Marpai Health, for this week's episode of Tuning In to the C-Suite podcast. The two talked about the significance of AI and deep learning in healthcare and how they will benefit the self-insurance market.

In this part three video series, Civica Rx CEO Martin VanTrieste says Civica is launching an outpatient retail market with its first retail drug coming to the market next year.

Ian E Krop, MD, PhD, elaborates on which treatment settings are most appropriate to use HER2-targeted therapies in to manage metastatic breast cancer.

Considerations regarding how to best integrate newer targeted therapies available for HER2-positive metastatic breast cancer [MBC] into clinical practice.

Editors of MHE and their furry friends had the pleasure of speaking with Dr. Glenn Levine, professor of medicine at Baylor College of Medicine and chief of the cardiology section at Michael E. DeBakey VA Medical Center in Houston. Dr. Levine is also a volunteer medical expert for the American Heart Association’s Healthy Bond for Life initiative and is lead author of the Association’s Scientific Statement on Pet Ownership and Cardiovascular Risk. In the conversation, Dr. Levine shared some wellbeing tips on how our pets can benefit our mental and physical health and wellbeing.

Civica Rx CEO Martin VanTrieste says Civica’s members are experiencing fewer shortages because of strategies used by the company.

Civica Rx is using long-term contracts and payment on delivery as a way to keep manufacturers in the market, Civica Rx CEO and president Martin VanTrieste said in an interview with MHE.

Glaucoma affects many people across the globe, but primarily, it's affecting African Americans due to access.

Briana Contreras, associate editor of Managed Healthcare Executive, spoke with Mark Poling, chief product officer of Zipari, a health insurance tech organization, about how a direct-to-consumer model can simplify the enrollment process. He also shared the benefits the model has to health insurance systems’ operations.

Ian E. Krop, MD, PhD, of Dana-Faber Cancer Institute, highlights more recent targeted therapy approvals for HER2-positive metastatic breast cancer and describes how each therapy is designed to work.

Frontline therapies available for newly diagnosed HER2-positive metastatic breast cancer and variables that impact treatment selection.

In this week's episode Senior Editor Peter Wehrwein chats with Founder and Executive Chairwoman of Caravan Health Lynn Barr. The two discussed the relationship of payers and ACOs and the approach toward the direct contracting model.

Biden is proposing a $46 million increase to the Ryan White HIV/AIDS Programs and $20 million for HUD’s Housing Opportunities for Persons with AIDS program. However, no increases were planned for hepatitis programs.

In this week’s episode of Tuning In to the C-Suite podcast, MHE Associate Editor Briana Contreras spoke with Ash Shehata, KPMG’s national sector leader for healthcare & life sciences. The two chatted about a recent paper by KPMG titled “From payor to healthcare partner,” which highlights how the pandemic drove changes for plans to adopt a patient-centric model and it gives a look into the six healthcare trends to watch for in 2021.